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Human epididymis protein 4 (HE4) is an important clinical biomarker used for the detection of epithelial ovarian cancer (EOC). While much is known about the predictive power
of HE4 clinically, less has been reported regarding its molecular role in the progression
of EOC. A deeper understanding of HE4’s mechanistic functions may help contribute to
the development of novel targeted therapies. Thus far, it has been difficult to recommend
HE4 as a therapeutic target owing to the fact that its role in the progression of EOC has
not been extensively evaluated. This review summarizes what is collectively known about
HE4 signaling and how it functions to promote tumorigenesis, chemoresistance, and
metastasis in EOC, with the goal of providing valuable insights that will have the potential
to aide in the development of new HE4-targeted therapies.
Keywords: human epididymis protein 4, epithelial ovarian cancer, tumorigenesis, chemoresistance, metastasis

INTRODUCTION
Approximately 22,280 new cases of epithelial ovarian cancer (EOC) are diagnosed each year, resulting in 14,240 deaths annually in the United States (1). The 5-year survival rate for stage III ovarian
cancer is only 39% (1). These dire statistics are due to the fact that the disease is frequently detected
at an advanced stage, which drastically impacts overall patient survival. Initially, many patients
respond well to first-line therapy that includes cytoreduction surgery and platinum-based treatment.
However, many patients experience a chemoresistant recurrence within the first 2 years following
treatment (2). Therefore, there is an urgent need for tools to aid in the early diagnosis of ovarian
cancer when the disease is fundamentally curable, as well as improved treatment options for later
stage disease.
Human epididymis protein 4 (HE4) is a secretory protein that is member of the whey acidic
protein domain family, bearing a conserved motif found in a number a protease inhibitors (3). HE4
was initially suggested to be involved in the innate immune defense of multiple epithelia and has
also been found to function in epithelial host defense (4). In ovarian tissue, HE4 is highly overexpressed in EOC compared normal tissue (5, 6). Clinically, HE4 has been identified as a novel
therapeutic biomarker for EOC and has also proven useful in detection of recurrent disease (7)
Serum HE4 level predicts EOC with equal sensitivity to the established biomarker CA125 and is less
likely to be elevated in benign disease (5). A multicenter study led by our institution established the
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FDA-approved Risk of Ovarian Malignancy Algorithm (ROMA),
which combines menopausal status and serum levels of both HE4
and CA125 to detect and monitor EOC. ROMA demonstrates
improved sensitivity and specificity over the Risk of Malignancy
Index that uses CA125 alone as a serum based biomarker (6).
Recently, it has been reported that HE4 can be detected in EOC
patient urine, indicating the possibility that it may be utilized as
a non-invasive biomarker (8).
While HE4 has been well studied in the clinical setting, less
is known regarding its specific molecular and biological roles
in EOC. Several studies have investigated its effect on gene
expression in EOC cells, as well as on events associated with
aggressive disease. This review will summarize HE4’s effect on
cell proliferation and tumor growth; invasion, migration, and
adhesion; chemoresistance; and steroid biosynthesis (Figure 1).
Each section will detail associated pathways and factors that are
reported to be involved in these HE4-mediated effects, with the
goal of revealing common themes in signaling pathways affected
by HE4 and exposing gaps in our knowledge of HE4 molecular
and biological functions.

HE4-mediated cell proliferation and tumor growth can be found
in Table 1A and is outlined in greater detail below.

Associated Pathways and Factors—Cell
Proliferation and Tumor Growth

Human epididymis protein 4 has been connected to several
oncogenic signaling cascades that play key roles in ovarian cancer
progression, including the PI3K/AKT pathway, HIF1α, and ERK/
mitogen-activated protein kinase (MAPK) signaling. Evidence of
HE4’s effect on activation of each of these pathways is discussed
below.

Protein Kinase B Signaling

AKT has been established as a strong promoter of tumorigenesis, and the PI3K/AKT pathway is one of the most commonly
hyperactivated pathways in many types of human cancers (16).
Its diverse signaling regulates proliferation, growth, survival,
motility, angiogenesis, and glucose metabolism (17). HE4overexpressing OVCAR3 ovarian cancer cells were found to
have a marked increase in activation of protein kinase B (AKT)
compared with control cells, while HE4 knockdown in OVCAR3
cells reduced AKT activation (12). Moreover, it was found that
HE4-overexpressing SKOV3 clones had naturally higher gene
levels of AKT3 compared with the null-vector control (18), bolstering the claim that HE4 affects the PI3K/AKT pathway.

CELL PROLIFERATION AND TUMOR
GROWTH
Within the past 5 years, a handful of in vitro and in vivo studies
have begun to examine HE4’s role in proliferation and tumor
growth in EOC. A study by Wang et al. examined the role of HE4
in cell proliferation and found that cells treated with recombinant
HE4 formed a statistically greater number of colonies compared
with control treated cells (9). Furthermore, cells stimulated with
recombinant HE4 exhibited greater cell viability compared with
respective controls. In another study by Zhu et al. (10), proliferation rate in two different HE4-overexpressing cell lines was
significantly higher than in the control cells. Likewise, Zhu et al.
(11) and Lee et al. (12) determined that when HE4 was ablated
via shRNA, cell proliferation decreased accordingly. Kong et al.
report conflicting results, stating that HE4 inhibits proliferation
in ovarian cells (13); however, no other studies support these
claims, necessitating further explanation to understand the
implications of their results.
Several in vitro studies suggest that HE4 promotes proliferation
through its involvement in cell cycle regulation (11). Silencing of
HE4 causes G0/G1 cell cycle arrest and blocks the transition from
the G1 to the S phase of the cell cycle. Conversely, when cells
are stimulated with recombinant HE4, the number of cells in the
G2/M phase is increased, while the number of cells in the G0/G1
phase is reduced (9). These results indicate that HE4 may mediate
the cell cycle by promoting the G0/G1 transition. In addition,
in vivo tumorigenicity studies using HE4 knockdown clones
revealed a marked inhibition in the growth of ovarian tumors in
nude mice (14), while injection of HE4-overexpressing cells led
to more aggressive tumor growth and an overall higher tumor
volume compared with controls (10, 15). Taken together, results
from numerous in vitro and in vivo studies provide compelling
evidence that HE4 plays a role in cell proliferation and the
promotion of tumorigenesis. A full list of factors associated with
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Hypoxia-Inducible Factor-1 Alpha (HIF1α)

Adaptation of malignant cells to hypoxic conditions is a key step
in the promotion of tumorigenesis and angiogenesis (19–21),
a process that is regulated by the transcription factor HIF1α.
Co-immunoprecipitation revealed an interaction between HIF1α
and HE4 in HE4-overexpressing SKOV3 xenografts. There was
also strong colocalization of HE4 and HIF1α in SKOV3 ovarian
xenograft tissue. In addition, when SKOV3 cells were treated with
HIF1α siRNA or 2-methoxyestradiol (a HIF1α inhibitor), there
was a marked decrease in HE4 protein levels (15). It is important
to note that 2-methoxyestradiol is not a specific HIF1α inhibitor as
it primarily causes the depolymerization of microtubules, which
in turn prevents HIF1α expression (22). Thus, the specificity of
the effect of HIF1α inhibition on HE4 levels may require further
investigation. Although the exact mechanism and significance
of the HE4-HIF1α interaction is not understood, this evidence
suggests that HE4 could play a role in regulating HIF1α functions
in angiogenesis.

MAPK Signaling

The MAPK pathway is composed of a family of conserved
kinases that mediate essential cellular processes such as migration, growth, proliferation, differentiation, and apoptosis (23).
The extracellular signal-regulated kinase (ERK) pathway is the
best characterized of all MAPK pathways and is deregulated
in approximately one-third of all cancers. Several studies have
shown activation of ERK in response to HE4 treatment or overexpression, or suppression of ERK phosphorylation in response
to HE4 knockdown (11, 12, 18). Using microarray analysis, Zhu
et al. determined that seven genes involved in the MAPK pathway (CHUK, GADD45A, IL1A, RPS6KA1, HSPA1B, DUSP1,
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Figure 1 | Graphical representation of clinical, in vivo and in vitro studies completed relating to HE4 and EOC, as well as associated pathways and mechanisms.
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Table 1 | Summary of factors associated with human epididymis protein 4 (HE4) in epithelial ovarian cancer (EOC).
Gene symbol

Description

(A) Cell proliferation and tumor growth
AKT
Protein kinase B

Association

• Upregulated in overexpressing OVCAR3 HE4 cell lines (10)
• Decreased in response to HE4 knockdown in OVCAR3 cells (10)
• Upregulated in HE4 SKOV3 clones compared with vector control (16)

HIF1α

Hypoxia-inducible factor-1 alpha

• Co-immunoprecipitation with HE4 SKOV3 xenograft tissue (13)
• Colocalization with HE4 in SKOV3 xenograft tissue (13)
• Treatment with 2-methoxyestradiol leads to marked decrease in HE4 (13)

ERK

Extracellular signal-regulated kinase

• Decrease in p-ERK when HE4 was silenced in SKOV3 cells (9)
• Corresponding decrease and increase in ERK when HE4 was
downregulated and overexpressed in OVCAR3 cells (10)
• Increase in p-ERK in SKOV3 and OVCAR8 cells with recombinant HE4 treatment (16)

CHUK
GADD45A

Conserved helix–loop–helix ubiquitous kinase
Growth arrest and DNA-damage-inducible
protein GADD45 alpha
Interleukin-1 alpha
Ribosomal protein S6 kinase alpha 1
Heat shock 70 kDa protein 1B,
Dual specificity protein phosphatase 1
Transcription factor JunD

• Upregulation when HE4 was induced in ES-2 cells (8)

EGF/EGFR

Epidermal growth factor/epidermal growth
factor receptor

•
•
•
•

VEGF
INS

Vascular endothelial growth factor
Insulin

• HE4 overexpressed in OVCAR8 cells when stimulated with recombinant protein (13)

IL1A
RPS6KA1
HSPA1B
DUSP1
JUND

(B) Invasion, migration, and adhesion
MMP-9
Matrix metallopeptidase 9
MMP-2
Matrix metallopeptidase 9
CTSB
Cathepsin B

Co-immunoprecipitation with HE4 SKOV3 xenograft tissue (13)
Colocalization with HE4 in SKOV3 xenograft tissue (13)
HE4 overexpressed in OVCAR8 cells when stimulated with recombinant protein (13)
HE4 increased when inhibited by IRESSA (13)

• Downregulated when HE4 is silenced in ovarian cell lines (9)

IL1A

Interleukin-1 alpha

• Microarray results reveal correlation with HE4 levels (8, 71)
• One microarray reports an inverse correlation with HE4 (16)

ITGβ5

Integrin β5

• Differentially regulated by HE4 in ES-2 and CaOV3 cells (8)
• Correlation with HE4 in paraffin embedded ovarian human tissue (8)

SDC1
COL1A1
DAG1

Syndecan 1
Collagen type 1 alpha 1
Dystroglycan 1

• Differentially regulated in response to HE4 (71)

LAMB3
LAMC2
GREM1
TNC
SERPIND2

Laminin-β3
Laminin-γ2
Gremlin 1
Tenascin C
Serine peptidase inhibitor member 2

• Increased expression when stimulated with recombinant
HE4 in OVCAR8 cells (57)

LAMA3

Laminin 332
Lewis y antigen

•
•
•
•

SERPIN D1

Heparin cofactor II

• Upregulated in HE4-overexpressing clones and downregulated in knockout
in in vitro lines (71)
• Spearman analysis revealed positive correlation with HE4 in human
EOC tissue immunohistochemistry staining (71)
• Poor patient prognosis when levels upregulated in combination with HE4 (71)

ANXA2

Annexin II

• Mass spectrometry and co-immunoprecipitation identify as strong interacting
partner of HE4 (58)
• Gene levels co-dependent with HE4 (58)
• Higher along with HE4 in EOC patients with lymph node metastasis than
those without (58)

Increased in response to HE4 stimulation of LAMB3 and LAMC2 (57)
Colocalized with HE4 in human ovarian tissue (98)
Immunohistochemistry stained found correlative staining with HE4 (98)
Overexpression promoted HE4-mediated invasion and metastasis in in vitro
cell lines (99)
• Knockdown promoted a decrease in invasion and metastatic properties
of HE4 (99)

(Continued)
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TABLE 1 | Continued
Gene symbol

Description

Association

LAMB2

Laminin subunit beta-2

• Gene levels decreased in presence of HE4 knockdown cell line (58)

MKN2

MAP kinase-interacting serine/threonine-protein kinase 2

(C) Chemoresistance
EGR1
Early growth response protein 1

• Suppressed in overexpressing HE4 clones (16)

p38

p38 mitogen-activated protein kinase

• Activated in NV cells treated with cisplatin and suppressed in
overexpressing HE4 clones (16)

BCL2

B-cell lymphoma 2

• Increased in response to recombinant HE4 in vitro (7)

BAX

bcl-2-like protein 4

• Decreased in response to recombinant HE4 in vitro (7)

MAPT
SEPT3

Microtubule-associated protein tau
Septin 3

• Upregulated in HE4-overexpressing clones (16)

TUBB

β-Tubulin

• Increased in response to recombinant HE4 in vitro (16)

ERK
AKT

Extracellular signal-regulated kinase
Protein kinase B

• Knockdown with HE4 lead to a reduction in cell growth and resensitization
to cisplatin and paclitaxel (10)

(D) Steroid biosynthesis
FOXA2
Forkhead box protein A2

• Differentially expressed in -overexpressing clones and knockouts (71)

SQLE
DHCR7
NSDHL

Squalene monooygenase
Dehydrocholesterol reductase
Sterol-4-alpha-carboxylate-3 dehydrogenase

• Differentially expressed in HE4-overexpressing clones and knockouts (71)

5-MC

5-Methylcytosine

• Downregulated in HE4-overexpressing clones compared with wild-type
SKOV3 cells and null vector (131)

ESR1

Estrogen/estrogen receptor

• Abolished in HE4-overexpressing clones (131)
• When stimulated in H08910 cells HE4 increased in gene and protein levels.
Effect not observed in SKOV3 cells (131)
• Increase expression in HE4 SKOV3 knockdown (131)

and JUND) were differentially regulated in response to HE4
overexpression in ES-2 cells (10).
Activation of the MAPK/ERK pathway occurs through EGF
binding of its membrane bound receptor, EGFR (24). Using
co-immunoprecipitation studies in SKOV3 cells, Moore et al.
found that HE4 interacts with EGFR, with a greater degree of
immunoprecipitation seen in HE4-overexpressing clones than
wild-type cells (15). Furthermore, ovarian xenograft tissue
showed colocalization of HE4 and EGFR. In addition, when
SKOV3 and OVCAR8 cells were stimulated with growth factors
EGF, VEGF, and Insulin, nuclear localization of HE4 was significantly increased. Finally, when EGF was repressed by the small
molecule inhibitor Iressa, relative intensity of HE4 staining was
decreased in ovarian cancer cell lines. Collectively, these results
provide several layers of evidence that HE4 is tied to growth
factor signaling and the MAPK/ERK pathway, although further
research is needed to elucidate the precise mechanisms involved.

cell growth, and DNA synthesis was increased prominently in
both cancer types (56). They also report that HE4 upregulates
gene expression of proliferating cell nuclear antigen (PCNA) and
downregulates p21 in both cancer cell lines in a dose dependent
manner. PCNA, which is expressed in the late G1/S phase of the
cell cycle, is required for DNA repair, replication, cell proliferation, and cell cycle progression (58), while p21 is an important
effector of tumor suppressor pathways by promoting cell cycle
arrest. Specifically, p21 is able to facilitate p53-dependent G1
growth arrest (59). Therefore, results from this study highlight
HE4’s role in proliferation in both pancreatic and endometrial
cancer and lend support to similar evidence from studies published on EOC.

INVASION, MIGRATION, AND ADHESION
Several studies have associated HE4 with metastatic properties,
including invasion, migration, and adhesion of ovarian cancer
cells. Lu et al. found that adhesion to a fibronectin substrate was
twofold greater in SKOV3 cells overexpressing HE4 than in mock
cells. In addition, a transwell migration assay demonstrated that
the HE4-overexpressing clones had a 1.8-fold greater migration
capacity than mock transfected cells. By contrast, immunofluorescence analysis showed that HE4 knockout clones displayed
inhibited cell-spreading ability in a statistically significant fashion
compared with respective controls. Furthermore, cell invasion,
proliferation, and migration were significantly decreased in
these clones (14). In agreement with this study, Ribeiro et al.

HE4’s Role in Proliferation in Other
Cancers

Human epididymis protein 4 has been investigated as a putative
biomarker in endometrial (25–39), lung (40–52), breast (53, 54),
pancreatic (55, 56), and gastric cancer (57). While the majority
of these studies examine the value of HE4 as a clinical biomarker
for detecting and monitoring disease, one study investigated the
molecular mechanisms of HE4 in pancreatic and endometrial
cancer. Lu et al. stimulated both pancreatic and endometrial cancer cell lines with recombinant HE4 and found that cell viability,
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also found that OVCAR8 ovarian cells treated with recombinant
HE4 exhibited 2.07-fold greater invasion capacity and 1.29-fold
greater adhesion to a fibronectin matrix compared with untreated
controls. Interestingly, there was no change in adhesion to collagen I, IV, laminin I, and fibrinogen matrices, suggesting that HE4
has a specific effect on fibronectin adhesion. Haptotaxis toward
a fibronectin substrate also was increased in the ovarian cancer
cells treated with recombinant HE4 by 1.72-fold (60).
Zhu et al. used wound healing and transwell invasion assays
to show that HE4-overexpressing ES-2 and CaOV3 cells possess
enhanced cell migration and invasion capacities. In addition,
in vivo tail vein injection of HE4-overexpressing ES-2 cells into
nude mice resulted in significantly more metastatic lung nodules
than mock transfected cells (10). Using the same ovarian cancer
cell lines, Zhuang et al. report the importance of HE4 interaction
with annexin II (ANXA2) to promote invasion and migration
in vitro and metastasis in vivo (61). Finally, Zou et al. found that
knockdown of HE4 in SKOV3.ip1 cells inhibited migration and
invasion (62). Taken together, these studies strongly suggest that
HE4 plays a prominent role in the promotion of ovarian cancer
metastasis. A full list of factors associated with HE4-mediated
invasion, migration, and adhesion can be found in Table 1B and
is outlined in greater detail below.

levels positively associated with HE4 levels (10, 74), while in one
study their levels were inversely associated (18). While there may
be some ambiguity as to how HE4 and IL1A are mechanistically
linked, the consistent connection between IL1A with HE4 merits
further investigation.

Extracellular Matrix Proteins

Integrins are a family of transmembrane proteins that are vital
to ECM adhesion and play important roles in wound healing as
well as the pathogenesis of cancer (75–77). Integrin β5 (ITGβ5)
gene expression was differentially regulated by HE4 in ES-2 and
CaOV3 cells, which was confirmed by positive correlation of
ITGB5 and HE4 staining in paraffin embedded ovarian tissue
samples (10). This finding suggests that integrin signaling is
one mechanism by which HE4 can promote increased adhesion
of ovarian cancer cells. However, further research is needed to
clarify the mechanisms involved.
In addition to ITGβ5, three other genes related to ECM modeling—syndecan 1 (SDC1), collagen type 1 alpha 1 (COL1A1),
and dystroglycan 1 (DAG1)—were more highly expressed in cells
overexpressing HE4 and were downregulated in cells with HE4
knockdown (10). SDC1, also known as CD138, is an essential
cell surface adhesion molecule that is responsible for maintaining
cell morphology and interactions within the surrounding microenvironment (78). Loss of SCD1 in cancer cells is associated with
reduced ECM adhesion and enhanced invasion and cell motility
(79). Another ECM gene found to be affected by HE4 expression
levels, COL1A1, is a crucial component of the ECM as it supports
cartilage, bone, and tendon tissues in the body and also functions
to maintain the rigidity and elasticity of tissues (80, 81). COL1A1
plays an important role in cancer, since tumor cells that express
COL1A1 are able to dissociate from their surrounding stromal
components, which is essential for tumor growth (81). The final
ECM gene found to be affected by HE4 is DAG1, which is a cell
adhesion molecule that plays a key role basement membrane
assembly (82), muscle integrity (83), and the maintenance of
basolateral cell adhesion in numerous epithelial tissues (84).
Loss of DAG1 is associated with cancer progression (85). Taken
together, these results show that HE4 is strongly interconnected
with ECM related proteins, specifically those involved in the
ITGβ5 signaling pathway.
Our lab has also determined that HE4 regulates several components of the extracellular matrix (60). We performed microarray
analyses comparing untreated OVCAR8 wild-type cells to recombinant HE4 treated cells, and OVCAR8 cells overexpressing HE4
to null-vector control cells. Serpin peptidase inhibitor, member
2 (SERPINB2), gremlin 1 (GREM1), laminin-β3 (LAMB3),
laminin-γ2 (LAMC2), fibroblast growth factor 5 (FGF5), and
tenascin C (TNC) were all found to be significantly upregulated
upon treatment with recombinant HE4. These genes encode
for extracellular matrix proteins that promote cell migration
and adhesion (60). Specifically, we found that HE4 upregulates
LAMC2 and LAMB3 proteins in a time-dependent manner,
and this increase of both factors in turn leads to an increase in
laminin-332 levels (60). Laminin-332, a heterotrimer composed
of LAMC2, LAMB3, and LAMA2, is an important component of
the basement membrane in epithelial tissue. Abnormal increases

Associated Pathways and Factors—
Invasion, Migration, and Adhesion

Human epididymis protein 4 appears to interact with numerous
molecular pathways that promote metastasis in ovarian cancer.
However, it is still not entirely known how HE4 affects signaling
pathways and gene expression signatures to promote invasion,
migration, and adhesion of ovarian cancer cells. Following is a
summary of HE4-mediated molecular pathways that are involved
in metastatic events in EOC.

Matrix Metalloproteinases (MMPs)

Human epididymis protein 4 has been associated with MMPs
MMP-9 and MMP-2, and Cathepsin B. MMPs are a family of
zinc-dependent endopeptidases that are vital for the remodeling
of the extracellular matrix (63). They are expressed in almost all
types of cancers and are responsible for stimulating angiogenesis,
tumor growth, and metastasis (64, 65). Cathepsin B is a lysosomal
cysteine protease that has been linked to cancer progression (66),
specifically in signaling pathways related to angiogenesis (67).
In addition, it can promote MMP activity by degrading MMP
inhibitors (68). Interestingly, silencing of HE4 in ovarian cancer
cells led to a decrease in protein levels of MMP-9, MMP-2, and
Cathepsin B, suggesting these factors may be involved in HE4mediated tumor promoting effects (11).

Interleukin-1 Alpha (IL1A)

Interleukin-1 alpha is a pro-inflammatory cytokine that is
involved in angiogenesis and metastasis. ILIA can directly
stimulate the synthesis of VEGF (69) and fibroblastic pro matrix
metallic proteinase I (70, 71). IL1A causes resistance to EGFR
inhibitors in both colon and head and neck cancers (72, 73). IL1A
was also found to be differentially expressed in three separate
microarray studies involving HE4. In two microarrays, IL1A
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in its levels have been shown to promote increased invasion in
cancers (86). Further evidence suggested involvement of the FAK
pathway in these events. In addition, activation of matriptase, a
serine protease responsible for cleaving laminin-332 in its β chain
and regulating its effects on metastatic properties, increased upon
in vitro exposure to recombinant HE4 (60). This study provides
compelling evidence that HE4 is involved in basement membrane
invasion and adhesion.

Annexin II

Annexin II is a calcium-dependent, phospholipid-binding protein that is overexpressed in a variety of cancers and is involved
in angiogenesis, proliferation, apoptosis, cell migration, invasion,
and adhesion (105). High levels of Annexin II activate MAPK
signaling, which in turn promotes tumor proliferation (106),
invasion (107), and metastasis (108). Zhuang et al. employed mass
spectrometry and co-immunoprecipitation to identify Annexin II
(ANXA2) as a strong HE4 interacting partner (61). This binding
promoted invasion and metastasis in ES-2 and CaOV3 ovarian
cancer cells. HE4 and ANXA2 gene expression levels were found
to be co-dependent, and examination of EOC tissue revealed that
both HE4 and Annexin II levels were increased in malignant phenotypes compared with benign and normal ovarian tissues. Both
proteins were also more highly expressed in tissues from patients
with lymph node metastases than those without. Downregulation
of HE4 was found to decrease expression of MKNK2 (MAP
kinase-interacting serine/threonine-protein kinase 2) and
LAMB2 (laminin, beta-2), two factors associated with MAPK
and focal adhesion signaling pathways. When HE4 protein was
supplemented, this effect was reversed. Collectively, these results
show that HE4 interaction with Annexin II to activate MAPK and
focal adhesion signaling is one mechanism by which HE4 may
promote ovarian cancer metastasis.

Lewis y Antigen

Human epididymis protein 4 undergoes glycosylation before
it is secreted by ovarian cells (87), prompting Zhuang et al. to
examine the relationship between HE4 glycosylation status and
metastatic properties. Lewis y antigen is a glycosyl antigen that
is overexpressed in ovarian cancer and has been associated with
chemoresistance and poor prognosis (88–97). They determined
that Lewis y antigen was present in HE4 from benign and malignant ovarian tissues, in vitro cancer cells, and culture medium.
HE4 from ovarian cancer samples contained higher levels of
Lewis y antigen than HE4 from benign tissues, and their expression co-localized in ovarian cancer tissue (98). Furthermore,
when Lewis y antigen was over expressed, it promoted HE4mediated invasion and metastasis in ovarian cancer cell lines.
Conversely, when Lewis y antigen was blocked, the invasive and
metastatic properties of HE4 were significantly decreased (99).
Interestingly, overexpression of Lewis y antigen increased tyrosine phosphorylation of EGFR and HER/neu, which promoted
cell proliferation through the PI3K/Akt and Raf/MEK/MAPK
pathways (100). Thus, it appears that Lewis y antigen and HE4
affect similar signaling pathways that promote tumor growth and
malignancy (101). Taken together, these results show that Lewis
y antigen could be a potential therapeutic target to decrease HE4
function in the treatment of EOC.

CHEMORESISTANCE
Several studies show that HE4 is associated with chemoresistance
clinically. The addition of HE4 serum levels in the ROMA score
better predicts platinum resistance in patients than CA125 alone
(15). Angioli et al. found that HE4 was able to predict chemotherapy response in EOC patients undergoing first-line therapy
(109). In addition, higher levels of serum HE4 are reported in
women who are resistant to first-line chemotherapy (110). Finally,
higher HE4 levels inversely correlate with clinical outcome (111),
optimal cytoreduction (112), progression free survival (113), and
overall survival (15, 113). While the mechanism underlying HE4’s
contribution to chemoresistance has not been established fully, a
few studies have begun to delineate HE4’s role in this process. A
full list of factors associated with HE4-mediated chemoresistance
can be found in Table 1C and is outlined in detail below.

Heparin Cofactor II (HCII)

SERPIND1 encodes for the protein HCII, which is a serum
glycoprotein and protease inhibitor (102). A study in non-small
cell lung cancer (NSCLC) showed that HCII promotes cell motility, invasion, and filopodium dynamics through the PI3K/AKT
pathway. High HCII expression in NSCLC tissue correlated to
an increased recurrence rate and shorter overall survival (103).
Furthermore, its levels were upregulated in metastatic brain cell
lines compared with non-metastatic parental lines, suggesting an
involvement of SERPIND1 in metastatic functions (104). Results
from a microarray study by Zhu et al. showed that SERPIND1
was upregulated in HE4-overexpressing cells and conversely
downregulated in HE4 knockdown cells. These results were
validated via qPCR and immunohistochemistry. In addition,
they found that 37/50 ovarian cancer samples showed positive
expression of both SERPIND1 and HE4, and Spearman correlation analysis confirmed that HE4 and SERPIND1 were positively
correlated. Finally, Kaplan–Meier analysis revealed that patients
with high levels of HE4 and SERPIND1 had a worse prognosis
(74). While these data strongly suggest a connection between
HE4 and SERPIND1, which may be related to their roles in promoting ovarian cancer metastasis, further study of the association
between these two proteins is required.

Frontiers in Oncology | www.frontiersin.org

Associated Pathways and Factors—
Chemoresistance
Antiapoptotic Gene Expression

A study performed in our lab by Ribeiro et al. determined that
HE4 overexpression promotes collateral chemoresistance to
both cisplatin and paclitaxel in SKOV3 and OVCAR8 cells
(18). Conversely, CRISPR/Cas9 mediated knockdown of HE4
in SKOV3 cells overexpressing HE4 partially reversed their
chemoresistance. Microarray analysis revealed suppression of
cisplatin-induced early growth response 1 (EGR1) gene expression in HE4-overexpressing SKOV3 cells compared with null
vector-transfected cells (18). EGR1 is a transcription factor that
regulates apoptosis, proliferation, and differentiation through
regulating expression of genes such as p53, BCL2, PTEN, IGF2,
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PDGF, VEGF, TGFB1, and TNF (114, 115). EGR1 expression
is influenced by MAPK signaling, including phospho-ERK and
phospho-p38 (115). Ribeiro et al. found that p38 was strongly
activated in SKOV3 null vector-transfected cells treated with cisplatin, while its activation was suppressed in HE4-overexpressing
clones (18), suggesting that HE4-mediated chemoresistance may
involve MAPK signaling.
Similarly, a study by Wang et al. showed that HE4 represses
carboplatin-induced apoptosis in vitro. Recombinant HE4 caused
an increase in expression of antiapoptotic protein B-cell lymphoma 2 (BCL-2) and a decrease in expression of pro-apoptotic
Bax (Bcl-2 associated X protein) in SKOV3 cells treated with
carboplatin (9). This decrease in the Bax/Bcl-2 ratio, in addition
to the suppression of EGR1 when HE4 is overexpressed, may
contribute to the overall decrease in pro-apoptotic factors that
leads to chemoresistance in EOC.

the promotive effect of estrogens on ovarian tumors in mice and
human EOC cell lines (122). However, activation of diverse oncogenic pathways in EOC may lead to the eventual downregulation
of ERα levels and the overall decrease in ERα related signaling
in ovarian cancers, rendering them resistant to anti-estrogen
therapies (122). Some evidence exists that HE4 may be involved
in this process by regulating steroid signaling in EOC. A full list
of factors associated with HE4-mediated steroid biosynthesis can
be found in Table 1D and is outlined in detail below.

Steroid Biosynthesis Gene Expression

Two separate microarray pathway analyses identified steroid biosynthesis as a pathway affected by HE4 (10, 74). Important genes
that were differentially expressed between HE4-overexpressing
and HE4 knockdown cell lines were Forkhead box protein A2
(FOXA2) (74), squalene monooygenase (SQLE), 7-dehydrocholesterol reductase (DHCR7), 24-dehydrocholesterol (DHCR24),
and sterol-4-alpha-carboxylate-3-dehydrogenase (NSDHL) (10).
FOXA2, a transcription factor required for normal metabolism
(123), promotes cell proliferation, maintains cancer stem cells,
and is associated with a higher rate of relapse in triple-negative
breast cancer (124).
Another gene differentially regulated by HE4, SQLE, is
an enzyme required in the later stages of cholesterol synthesis
(125). Out of 22 cancer types, SQLE copy number-driven gene
expression was highest in breast, ovarian and colorectal cancer
(125). Also affected by HE4 levels was DHCR7, one of the terminal enzymes involved in the production of cholesterol from
7-dehydrocholesterol (7DHC). DHCR7 was found to be an
important regulatory determinate between cholesterol and vitamin synthesis, as cholesterol is able to accelerate the proteasomal
degradation of DHCR7, which can result in the accumulation of
7DHC and an increased production of vitamin D (126). DHCR24,
which was also affected by modulation of HE4 levels, is another
enzyme in the cholesterol biosynthesis pathway (127). It interacts
physically and functionally with DHCR7 (128) and has a number
of different cellular functions including anti-inflammatory and
antiapoptotic functions, as well as regulation of oxidative stress
and cell differentiation (129). DHCR24 has also been proposed
to be involved in tumor progression, as its deregulation has been
linked to prostate, ovarian, and urothelial carcinomas (127).
Finally, NSDHL is also involved in cholesterol biosynthesis
and produces metabolites that are essential in the conversion of
squalene to cholesterol (130). Interestingly, NSLD1 was found
to have a role in the control of signaling, vesicular trafficking,
and degradation of EGFR and its dimerization partners ERBB2
and ERBB3. A study by Sukhanova et al. showed that NSLD1
knockout in vivo leads to a reduction in EGFR activation (131).
The results from these microarrays show that modulating HE4
levels results in differential expression of several genes involved
in steroid biosynthesis—especially cholesterol—suggesting that
HE4 may affect tumor metabolism and ultimately contribute to
tumorigenesis.

Microtubule Stabilization

Microtubule-associated protein tau, which has been associated
with paclitaxel resistance in ovarian (116), breast (117), and
gastric cancer (118), was upregulated in SKOV3 cells overexpressing HE4 compared with null-vector cells (18). In addition,
HE4-overexpressing cells were found to express significantly
higher levels of SEPT3 (Septin 3) mRNA compared with nullvector controls (18). Septins are a family of conserved GTP
binding proteins that are associated with microtubules and actin
filaments and have an important role in cytoskeletal organization
(119). Furthermore, recombinant HE4 treatment of SKOV3 cells
increased β-tubulin levels, indicating that HE4 might promote
microtubule stability, leading to paclitaxel resistance.

Kinase Signaling Pathways

Human epididymis protein 4 knockdown has also been shown
to lead to a reduction in cell growth and the resensitization of
ovarian cancer cells to both cisplatin and paclitaxel (12). Lee
et al. found that this effect was due to corresponding decreases of
ERK and AKT in HE4 knockouts. Activation of these pathways
suppresses apoptotic signaling in tumors, suggesting that HE4’s
regulation of these pathways may be an important mechanism of
chemoresistance (120).

STEROID BIOSYNTHESIS
Evidence suggests an association between sex steroids and EOC
pathogenesis, which is explained by processes that take place
during the menstrual cycle. The ovarian surface epithelium
(OSE) plays a critical role in ovulation and postovulatory wound
repair. During the menstrual cycle, the OSE proliferates during
the pro-estrus/estrus transition. After, ovulation the proliferation rate decreases (121). It is hypothesized that when the OSE
is repeatedly exposed to high doses of luteinizing hormone and
follicle stimulating hormone during the menstrual cycle, this can
promote cell proliferation and increase the likelihood of tumor
growth over time (121). Furthermore, epidemiological data
have suggested that ovarian cancer progression, pathogenesis,
and etiology are highly dependent on the activity of estrogens
(121), and numerous experimental studies have demonstrated
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In support of the above described pathway analyses, two other
studies have shown that HE4 interacts with steroid signaling,
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specifically estrogen signaling. Lokich et al. showed that ERα
expression was reduced in HE4-overexpressing SKOV3 cells,
resulting in increased resistance to tamoxifen and fulvestrant
compared with wild-type cells (132). 5-Methylcytosine (5-MC),
a methylated form of the DNA base cytosine, is one of the most
prominently identified epigenetic modifications, and can cause
suppression of ERα gene expression. Deregulation of DNA
methylation can result in abnormal gene expression and tumorigenesis (133, 134). Lokich et al. found that 5-MC was readily
detected in SKOV3 wild-type and null-vector cells but not in
HE4-overexpressing clones, suggesting that HE4 overexpression
may have an effect on epigenetic modifications (132). However,
methylation of the ERα gene was not specifically examined in this
study. It is unclear whether HE4 overexpression would promote
increased methylation at the ERα promoter region (even with
the presence of global demethylation), which would be expected
given the reported suppression of ERα in this study.
Interestingly, Chen et al. reported that when HO8910 ovarian
cancer cells were stimulated with estradiol (E2), there was an
increase in the expression of HE4 at the mRNA and protein level.
This effect was not observed in estrogen-insensitive SKOV3 cells;
however, when HE4 was knocked down in SKOV3 cells, their
proliferative response to estrogen was restored (135). Collectively
with the results shown by Lokich et al, this study suggests that
HE4 works to suppress estrogen signaling in ovarian cancer cells,
which can contribute to resistance to anti-estrogen therapies.
Conversely, it appears that estradiol promotes HE4 expression in
estrogen-responsive cells, which could indicate a role for HE4 in
the initial tumor promoting effects of estrogen. Further clarification of the effect of HE4 on estrogen signaling may be useful in
improving implementation of anti-estrogen based therapies.

has yet to be a breakthrough targeted therapy to combat EOC.
While PARP inhibitors are used in the maintenance setting for
all patients, this therapy has most significantly benefited BRCApositive patients, who comprise only 20–25% of patients (137,
138). In addition, inhibitors of immune checkpoints, such as
programmed death ligand-1 have demonstrated modest benefit
in clinical trials for ovarian cancer (139). Therefore, there is still
a crucial need for novel targeted EOC treatments.
Although HE4 is well established as a clinical biomarker
for ovarian cancer, it has been largely understudied for its
therapeutic targeting potential. However, ongoing research
continues to support that HE4 is profoundly involved in the
pathogenesis of EOC. The individual studies mentioned in this
review provide evidence that HE4 promotes EOC progression
through pathways associated with cell proliferation, tumor
growth, metastasis, chemoresistance, and steroid biosynthesis.
These pathways, along with specific genes that have been shown
to be associated with HE4, are summarized in Table 1. This
compilation of HE4 regulated factors and pathways will serve
as a starting point for scientists to further elucidate specific
mechanisms by which HE4 ultimately drives tumorigenesis.
In addition, a comprehensive summary of clinical, in vivo, and
in vitro studies related to each facet of EOC progression and HE4
can be seen in Figure 1. This diagram highlights the progress
that has been made to establish HE4 as an attractive therapeutic
target, while simultaneously denoting areas of research that are
still lacking. The results discussed here suggest that inhibition
of HE4 via a neutralizing antibody or small molecule inhibitor
could provide viable treatment options for patients in dire need
of more effective therapies.
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Ovarian cancer is an extremely deadly disease owing to the fact
that patients are typically diagnosed at a late stage. Initially,
patients respond well to frontline platinum therapy; however, a
majority of tumors recur, and the initial chemosensitivity eventually gives way to a broad chemoresistance (136). Available detection methods have improved in recent years with the discovery
of HE4 as a diagnostic and prognostic biomarker. However, there
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